Tea consumption offers protective effects on mortality among patients with chronic kidney disease, according to study findings.

The following is a summary of “Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study,” published in the January 2025 issue of Cardiology by ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

According to a 2019 review, up to 84% of people with end stage chronic kidney disease develop pruritus. The authors state that recent advancements in dialysis treatments have helped bring the ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).